Search Results - "Irving, Julie A.E"

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia by Case, Marian, Matheson, Elizabeth, Minto, Lynne, Hassan, Rosline, Harrison, Christine J, Bown, Nick, Bailey, Simon, Vormoor, Josef, Hall, Andrew G, Irving, Julie A E

“…Deregulation of the RAS-RAF-mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK signaling cascade is often caused by…”
Get full text

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells by Brito, Jose L.R, Walker, Brian, Jenner, Matthew, Dickens, Nicholas J, Brown, Nicola J.M, Ross, Fiona M, Avramidou, Athanasia, Irving, Julie A.E, Gonzalez, David, Davies, Faith E, Morgan, Gareth J

“…1 Institute for Cancer Research, Section of Haemato-Oncology, London 2 Department of Medical and Molecular Genetics, Division of Genetics and Molecular…”
Get full text

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia by Houlston, Richard S, Papaemmanuil, Elli, Hosking, Fay J, Vijayakrishnan, Jayaram, Price, Amy, Olver, Bianca, Sheridan, Eammon, Kinsey, Sally E, Lightfoot, Tracy, Roman, Eve, Irving, Julie A E, Allan, James M, Tomlinson, Ian P, Taylor, Malcolm, Greaves, Mel

“…To identify risk variants for childhood acute lymphoblastic leukemia (ALL), we conducted a genome-wide association study of two case-control series, analyzing…”
Get full text

Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM by Matheson, Elizabeth C, Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K, Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R, Vormoor, Josef, Irving, Julie A E

“…New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that…”
Get full text

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response by Dixon, Zach A, Nicholson, Lindsay, Zeppetzauer, Martin, Matheson, Elizabeth, Sinclair, Paul, Harrison, Christine J, Irving, Julie A E

“…Relapsed acute lymphoblastic leukemia is the most common cause of cancer-related mortality in young people and new therapeutic strategies are needed to improve…”
Get full text

Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor by Schmidt, Stefan, Irving, Julie A.E, Minto, Lynne, Matheson, Elizabeth, Nicholson, Lindsay, Ploner, Andreas, Parson, Walther, Kofler, Anita, Amort, Melanie, Erdel, Martin, Hall, Andy, Kofler, Reinhard

“…Glucocorticoids (GCs) specifically induce apoptosis in malignant lymphoblasts and are thus pivotal in the treatment of acute lymphoblastic leukemia (ALL)…”
Get full text

Association of Glucocorticoid Receptor Polymorphism A3669G in Exon 9β with Reduced Central Adiposity in Women by Syed, Akheel A., Irving, Julie A. E., Redfern, Christopher P. F., Hall, Andrew G., Unwin, Nigel C., White, Martin, Bhopal, Raj S., Weaver, Jolanta U.

“…The glucocorticoid receptor (GR) may be a common link between human obesity/metabolic syndrome and Cushing's syndrome. The effects of glucocorticoids are…”
Get full text

Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis by IRVING, Julie A. E, BLOODWORTH, Lisa, BOWN, Nick P, CASE, Marian C, HOGARTH, Linda A, HALL, Andrew G

“…Loss of heterozygosity (LOH) is detectable in many forms of malignancy, including leukemia, using techniques such as microsatellite analysis and comparative…”
Get full text

Loss of heterozygosity and somatic mutations of the Glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course by IRVING, Julie A. E, MINTO, Lynne, BAILEY, Simon, HALL, Andy G

“…Glucocorticoids are pivotal in the treatment of children with acute lymphoblastic leukemia (ALL) and have significant antileukemic effects in the majority of…”
Get full text

Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma by de Brito, Luis R, Batey, Mike A, Zhao, Yan, Squires, Matt S, Maitland, Helen, Leung, Hing Y, Hall, Andrew G, Jackson, Graham, Newell, David R, Irving, Julie A.E

“…Abstract Background Fibroblast growth factor receptor 3 (FGFR3) is up-regulated as a result of the t(4;14)(p16;q32) translocation that occurs in up to 20% of…”
Get full text

Mismatch repair and the downstream target genes, PAX5 and Ikaros , in childhood acute lymphoblastic leukemia by Best, Andrew, Matheson, Elizabeth, Minto, Lynne, Hall, Andrew G, Irving, Julie A.E

“…Abstract The mismatch repair (MMR) pathway is a post-replicative DNA repair process and MMR deficiency is a common feature of ALL cell lines. In this study we…”
Get full text

DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma by Velangi, Mark R., Matheson, Elizabeth C., Morgan, Gareth J., Jackson, Graham H., Taylor, Penelope R., Hall, Andrew G., Irving, Julie A.E.

“…Genetic instability is a prominent feature in multiple myeloma and progression of this disease from monoclonal gammopathy of uncertain significance (MGUS) and…”
Get full text

Crebbp K nockdown Does Not Impact on Glucocorticoid Induced Apoptosis in Childhood Acute Lymphoblastic Leukemia by Dixon, Zach, Irving, Julie A.E., Nicholson, Lindsay

“…Childhood acute lymphoblastic leukemia (ALL) is the most common childhood cancer and, despite a cure rate approaching 90%, relapse is a significant cause of…”
Get full text

Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia by Irving, Julie A. E.

“…Summary Acute lymphoblastic leukaemia is the most common childhood cancer and for those children who relapse, prognosis is poor and new therapeutic strategies…”
Get full text

Mismatch repair defects as a cause of resistance to cytotoxic drugs by Irving, Julie AE, Hall, Andrew G

“…In this short review, we aim to bring together the most recent evidence implicating mismatch repair pathway defects as a cause of drug resistance to a spectrum…”
Get full text

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia by Bell, Hayden L., Blair, Helen J., Jepson Gosling, Samantha J., Galler, Martin, Astley, Daniel, Moorman, Anthony V., Heidenreich, Olaf, Veal, Gareth J., van Delft, Frederik W., Lunec, John, Irving, Julie A. E.

“…Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential…”
Get full text

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia by Irving, Julie A.E., Enshaei, Amir, Parker, Catriona A., Sutton, Rosemary, Kuiper, Roland P., Erhorn, Amy, Minto, Lynne, Venn, Nicola C., Law, Tamara, Yu, Jiangyan, Schwab, Claire, Davies, Rosanna, Matheson, Elizabeth, Davies, Alysia, Sonneveld, Edwin, den Boer, Monique L., Love, Sharon B., Harrison, Christine J., Hoogerbrugge, Peter M., Revesz, Tamas, Saha, Vaskar, Moorman, Anthony V.

“…Somatic genetic abnormalities are initiators and drivers of disease and have proven clinical utility at initial diagnosis. However, the genetic landscape and…”
Get full text

SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain by Sinclair, Paul B., Ryan, Sarra, Bashton, Matthew, Hollern, Shaun, Hanna, Rebecca, Case, Marian, Schwalbe, Edward C., Schwab, Claire J., Cranston, Ruth E., Young, Brian D., Irving, Julie A. E., Vora, Ajay J., Moorman, Anthony V., Harrison, Christine J.

“…In more than 30% of B-cell precursor acute lymphoblastic leukaemia (B-ALL), chromosome 21 sequence is overrepresented through aneuploidy or structural…”
Get full text

Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial by Jackson, Rosanna K., Liebich, Martina, Berry, Philip, Errington, Julie, Liu, Jizhong, Parker, Catriona, Moppett, John, Samarasinghe, Sujith, Hough, Rachael, Rowntree, Clare, Goulden, Nick J., Vora, Ajay, Kearns, Pamela R., Saha, Vaskar, Hempel, Georg, Irving, Julie A.E., Veal, Gareth J.

“…The use of dexamethasone in acute lymphoblastic leukaemia therapy contributes to short- and long-term toxicities. The UKALL 2011 randomised trial investigated…”
Get full text

Molecular diagnostics: a healthcare perspective by Hall, Andrew G, Coulthard, Sally A, Irving, Julie A E

“…Recent progress in the development of molecular diagnostics in medicine has been rapid and the hope has been expressed by some people that it will soon be…”
Get more information